The corresponding author and colleagues constructed and tested a replication-competent vaccinia virus with an improved capacity to activate the interferon regulatory factor 3 (IRF3) pathway as a candidate cancer therapeutic, showing increased antitumor immune responses and the ability to destroy tumors in mouse models. Here, IRF3 is linked to cancer.